Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma.
Bartkowiak T, Brockman AA, Mobley BC, Harmsen H, Moots P, Merrell R, Johnson DB, Thompson RC, Puduvalli VK, Ihrie RA. Bartkowiak T, et al. Among authors: moots p. medRxiv [Preprint]. 2023 Dec 26:2023.12.08.23299732. doi: 10.1101/2023.12.08.23299732. medRxiv. 2023. PMID: 38234786 Free PMC article. Preprint.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
Salas LA, Stewart TG, Mobley BC, Peng C, Liu J, Loganathan SN, Wang J, Ma Y, Berger MS, Absher D, Hu Y, Moots PL, Christensen BC, Clark SW. Salas LA, et al. Among authors: moots pl. Cancer Res Commun. 2022 Jan;2(1):1-9. doi: 10.1158/2767-9764.CRC-21-0088. Cancer Res Commun. 2022. PMID: 35392283 Free PMC article. Clinical Trial.
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. Nabors LB, et al. Among authors: moots pl. J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166. J Natl Compr Canc Netw. 2017. PMID: 29118226
Clinical Reasoning: A 52-year-old man with diplopia and ataxia.
Bradshaw MJ, Pawate S, Bloch KC, Moots P, Reddy NM. Bradshaw MJ, et al. Among authors: moots p. Neurology. 2016 Sep 27;87(13):e140-3. doi: 10.1212/WNL.0000000000003150. Neurology. 2016. PMID: 27672172 No abstract available.
Central Nervous System Cancers, Version 1.2015.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. Nabors LB, et al. Among authors: moots pl. J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. doi: 10.6004/jnccn.2015.0148. J Natl Compr Canc Netw. 2015. PMID: 26483059
35 results